| 711528 |
CLINICAL LUNG CANCER |
Table of Contents |
2021-07-01 |
10.1016/s1525-7304(21)00154-6 |
|
| 711527 |
CLINICAL LUNG CANCER |
Deterioration in Health-Related Quality of Life Diminishes Benefit of Lung Cancer Resection in Older Adults. | Deterioration in Health-Related Quality of Life Diminishes Benefit of Lung Cancer Resection in Older Adults |
2021-07-01 |
10.1016/j.cllc.2020.06.022 |
Blakely Andrew M., Hu Hengrui, Wong F. Lennie, Raz Dan J., Erhunmwunsee Loretta, Sun Virginia, Kim Jae Y. |
| 711526 |
CLINICAL LUNG CANCER |
Brown-Séquard Syndrome in a Desmoplastic Malignant Mesothelioma Patient: A Rare Complication. | Brown-Séquard Syndrome in a Desmoplastic Malignant Mesothelioma Patient: A Rare Complication |
2021-07-01 |
10.1016/j.cllc.2020.09.019 |
Ralki Mike, Serrien Anouk, Lambert Julie, Leys Mathias, Nackaerts Kristiaan |
| 711525 |
CLINICAL LUNG CANCER |
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial |
2021-07-01 |
10.1016/j.cllc.2021.07.002 |
Wong Deborah J., Bauer Todd M., Gordon Michael S., Bene-Tchaleu Fabiola, Zhu Jing, Zhang Xiaosong, Cha Edward |
| 711524 |
CLINICAL LUNG CANCER |
Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature |
2021-07-01 |
10.1016/j.cllc.2021.06.011 |
Koopman Bart, Groen Harry J.M., Schuuring Ed, Hiltermann T. Jeroen N., Timens Wim, den Dunnen Wilfred F.A., van den Berg Anke, ter Elst Arja, van Kruchten Michel, Kluiver Joost L., Hiddinga Birgitta I., Hijmering-Kappelle Lucie B.M., Groves Matthew R., Vilacha Juliana F., van Kempen Léon C., van der Wekken Anthonie J. |
| 711523 |
CLINICAL LUNG CANCER |
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small |
2021-07-01 |
10.1016/j.cllc.2021.07.005 |
De Ruysscher Dirk, Ramalingam Suresh, Urbanic James, Gerber David E, Tan Daniel S.-W., Cai Junliang, Li Ang, Peters Solange |
| 711522 |
CLINICAL LUNG CANCER |
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC) |
2021-07-01 |
10.1016/j.cllc.2021.02.010 |
Garon Edward B., Cho Byoung Chul, Reinmuth Niels, Lee Ki Hyeong, Luft Alexander, Ahn Myung-Ju, Robinet Gilles, Le Moulec Sylvestre, Natale Ronald, Schneider Jeffrey, Shepherd Frances A., Garassino Marina Chiara, Geater Sarayut Lucien, Szekely Zsolt Papai, Van Ngoc Tran, Liu Feng, Scheuring Urban, Patel Nikunj, Peters Solange, Rizvi Naiyer A. |
| 711521 |
CLINICAL LUNG CANCER |
Second-line afatinib or chemotherapy following immuno-chemotherapy for the treatment of metastatic, squamous cell carcinoma of the lung: real-world effectiveness and safety from a multi-site retrospective chart review in the USA |
2021-07-01 |
10.1016/j.cllc.2021.02.006 |
Kim Edward S., Kish Jonathan K., Cseh Agnieszka, Moehring Barbara, Tang Wenbo, Terlizzi Elizabeth, Subramanian Janakiraman |
| 711520 |
CLINICAL LUNG CANCER |
Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status |
2021-07-01 |
10.1016/j.cllc.2021.01.013 |
Kerrigan Kathleen, Wang Xuechen, Haaland Benjamin, Adamson Blythe, Patel Shiven, Puri Sonam, Akerley Wallace |
| 711519 |
CLINICAL LUNG CANCER |
MET amplification (MET/CEP7 Ratio ≥1.8) Is an Independent Poor Prognostic Marker in Patients with Treatment-Naïve Non-Small Cell Lung Cancer |
2021-07-01 |
10.1016/j.cllc.2020.11.002 |
Yin Wei, Cheng Joanne, Tang Zhenya, Toruner Gokce, Hu Shimin, Guo Ming, Robinson Melissa, Medeiros L. Jeffrey, Tang Guilin |
